Status:
COMPLETED
Key Dimensions of PTSD and ED
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Trauma
PTSD
Eligibility:
All Genders
18+ years
Brief Summary
This study will test whether endothelial dysfunction could be the early subclinical mechanism by which posttraumatic stress disorder (PTSD) increases cardiovascular disease (CVD) risk, and whether pos...
Detailed Description
Posttraumatic stress disorder (PTSD) increases risk of incident cardiovascular disease (CVD) by 25-50%. Most individuals (50-90%) experience a traumatic event in their lifetime, and PTSD is the fifth ...
Eligibility Criteria
Inclusion
- Aged 18+ years
- History of exposure to a psychological trauma (e.g., natural disaster, physical assault)
- Fluent in English
- Willing to and capable of providing informed consent
- Additional Inclusion Criteria for the PTSD Group
- Diagnosed with current PTSD (duration of at least 1 month) using the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual 5th Edition (DSM-5) (CAPS-5) at the diagnostic interview assessment
Exclusion
- History of CVD (i.e., diagnosis of myocardial infarction, unstable angina, heart failure, peripheral artery disease, or stroke)
- Deemed unable to comply with the protocol (either self-selected or by indicating during screening that could not complete all requested tasks)
- Current bipolar disorder or psychotic disorder
- Mild or more severe cognitive impairment \[Mini-Mental State Exam (MMSE)3 score ≤18\]
- Current moderate or severe substance use disorder
- Acute, unstable, or severe medical disorder or pregnancy
- Deemed to need immediate psychiatric intervention (e.g., active suicidality)
- Use of antipsychotic, mood stabilizer, antidepressant, or stimulant medication in the past 4 weeks
- Daily benzodiazepine use in the past 2 weeks
- Additional Exclusion Criteria for the Trauma-Exposed Matched Control Group
- Current or past diagnosis of any DSM-5 psychiatric disorder
- CAPS-5 total score ≥25
Key Trial Info
Start Date :
November 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT03778307
Start Date
November 20 2019
End Date
June 30 2025
Last Update
October 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States, 90095